12/11
07:00 am
ppbt
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
High
Report
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
12/4
07:00 am
ppbt
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Medium
Report
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
11/29
12:31 am
ppbt
Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at
Wall Street Z
Medium
Report
Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at
Wall Street Z
10/29
07:33 am
ppbt
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
High
Report
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
10/20
04:00 pm
ppbt
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Low
Report
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification